RxDoctor Payments Data

Jonathan Aliota, MD

Interventional Cardiology · Houston, TXNPI 1598712812

Payments from drug & device makers

$106,229in general payments, 2019–2025

Across 291 payments — averaging $365.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$86K
  • Shockwave Medical, Inc$8K
  • Medtronic$3K
  • Abbott$3K
  • Abiomed$2K
  • Edwards Lifesciences$1K
  • plus $4K from 20 others

What the payments were for

  • Consulting fees$8,8508%
  • Speaking & faculty fees$69,93866%
  • Travel & lodging$10,91010%
  • Food & beverage$16,53216%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$106,229 in reported general payments places this provider in the 85th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$8,066
Medicare patients
52
Services billed
92

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban474$501,622
XareltoRivaroxaban283$267,112
EntrestoSacubitril/Valsartan49$68,343
Repatha SureclickEvolocumab66$47,935
Rosuvastatin Calcium513$24,361
BrilintaTicagrelor22$16,328
Pravastatin Sodium302$12,988
Praluent PenAlirocumab12$12,696
ClopidogrelClopidogrel Bisulfate448$12,266
Valsartan147$12,063
Atorvastatin Calcium271$8,510
Flecainide Acetate139$8,033
Losartan Potassium268$6,710
Metoprolol Succinate231$6,025
Amiodarone Hcl57$4,499

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$501,622474 claims
Johnson & JohnsonXarelto$250$267,112283 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →